Although hemorrhagic cystitis (HC) is a common complication of allogeneic hematopoietic cell transplantation (alloHCT), its risk factors and effects on survival are not well known. We evaluated HC in ...
Pittsburgh, Pennsylvania, United States , May 10, 2022 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for ...
Hemorrhagic cystitis (HC) is a frequent and sometimes life-threatening complication after hematopoietic SCT (HSCT). Many therapeutic approaches have been performed to control HC, but their effect is ...
PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the ...
Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...
BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, ...
Please provide your email address to receive an email when new articles are posted on . BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to posoleucel for the treatment of virus-associated hemorrhagic cystitis ...
Pelvic Cancer Induced Hemorrhagic Cystitis Market · GlobeNewswire Inc. The pelvic cancer induced hemorrhagic cystitis market size has experienced robust growth recently, increasing from $3.1 billion ...
(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...